TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Community
Main Feed
Today's Market Intel
Top Stocks
AI-Curated Stock Lists
IPO Calendar
Upcoming Listings
Stock Teasers
The Stock Behind the Promo
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
Stock Reports
AI Research Reports
Commentary
Opinionated Stock Takes
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Account
Plan, Billing & Appearance
Log inCreate Account
← Back to TickerSpark
▌Earnings Deep Dive·November 6, 2026

Humana Inc. (HUM) gains on deep earnings beat analysis

Humana Inc. (HUM) gained after a better-than-feared Q3 earnings beat, but the real story is the deeper recovery setup. Revenue improved sequentially, guidance rose, and management pointed to easing medical cost trends, stronger membership growth, and a clearer path to margin recovery.

Earnings Deep DiveHUMHealthcareMedical - Healthcare Plans
By TickerSpark·November 6, 2026·7 min read
Humana Inc. (HUM) gains on deep earnings beat analysis
▌Key Takeaway
Humana Inc. (HUM) posted a better-than-feared third quarter, with adjusted EPS of -$0.70 versus the -$1.00 consensus and revenue of $41.16 billion above estimates. The company also raised its 2026 adjusted EPS outlook to at least $9.50, signaling a firmer recovery path as medical cost trends improve and membership growth accelerates in key businesses. Investors viewed the print as a constructive step toward margin recovery, even though earnings remain volatile and the turnaround is still in progress.

Humana Inc. (HUM) gains after Q3 earnings beat

Humana Inc. (HUM) delivered a better-than-feared third quarter: adjusted EPS came in at -$0.70 versus the -$1.00 consensus estimate, while revenue reached $41.16B against $40.87B expected. HUM shares gained 3.82% to $427.50 in regular trading on Nov. 6, with 1,496,089 shares traded versus an average of 1,244,321, as the market absorbed higher guidance and a firmer recovery path.

Key Takeaways

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

  • HUM earnings beat both major estimates. Adjusted EPS was -$0.70 versus -$1.00 expected, while revenue was $41.16B versus $40.87B.
  • Revenue continued to build sequentially, rising from $39.65B in Q1 and $40.87B in Q2 to $41.16B in Q3.
  • Humana raised its 2026 adjusted EPS outlook to at least $9.50 from at least $9.00.
  • Management reported a 4.17 member-weighted Stars rating for BY28 and expects a one-time 2028 tailwind, with some funds directed to investment and shareholder returns.
  • CenterWell Primary Care added nearly 147,000 members, or 30% growth, while Medicaid membership increased by 104,000 in 2026.
  • Analyst sentiment remains mixed but constructive. The consensus rating is Hold, while Jefferies reiterated Buy with a $420 price target after the quarter.

Financial Performance: Revenue Growth and the EPS Bridge

The central HUM earnings result was a revenue beat paired with a smaller-than-expected loss. Revenue reached $41.16B, compared with $40.87B in Q2, $39.65B in Q1, $32.52B in Q4 2025, and $32.65B in the year-earlier quarter. The sequential increase gives the business a stronger top-line base as management works through Medicare Advantage margin pressure.

Profitability remained uneven. The quarterly financial series lists net income of $0.16B in Q3, down from $0.69B in Q2 and $1.19B in Q1. The same series lists EPS of $1.35 in Q3, $5.79 in Q2, $9.85 in Q1, -$6.61 in Q4 2025, and $1.62 in Q3 2025. Those figures differ from the -$0.70 adjusted EPS headline because Humana distinguishes GAAP and non-GAAP measures on its earnings call.

The earnings surprise history also shows why a single-quarter beat does not equal a normalized earnings profile. Actual EPS was $7.61 in Q2, $10.31 in Q1, -$3.96 in Q4 2025, and $3.24 in Q3 2025. The latest result improved against the -$1.00 estimate, but the wide quarterly swings keep the recovery story firmly tied to cost control and Medicare Advantage execution.

Humana's annual segment data shows the scale of its two main engines. Insurance Segment revenue reached $124.563B in 2025, up from $113.764B in 2024. CenterWell Segment revenue reached $22.473B, compared with $19.936B in 2024. Insurance remains the profit engine, while CenterWell provides a growing care-delivery platform that management is expanding through primary care and value-based models.

Cost trends supplied the more important margin signal. CFO Celeste Mellet said 2026 medical cost trend was running at the lower end of the 7% to 8% range. She cited better inpatient performance, including admissions and cost per admission, plus favorable Part D results. For 2027, the company expects trend to rise to 8% to 9%, with Part D trend at 14% to 15% because of the health technology pipeline.

Get AI research on any stock

Instant reports, daily intelligence, and an AI analyst in your pocket.

Get Started →

Market Reaction and Analyst Response

The regular-session market response was positive. HUM traded at $427.50, up 3.82%, while volume reached 1,496,089 shares versus an average of 1,244,321. That combination points to active buying after the EPS beat, the revenue beat, and the higher full-year outlook.

The broader analyst mix remains cautious. Consensus includes 21 Buy ratings, 22 Hold ratings, and one Sell rating, producing an overall Hold view. Jefferies provided the clearest immediate endorsement by reiterating Buy and keeping its $420 price target. Analyst David Windley said the Insurance Medical Loss Ratio came in about 40 basis points better than management guidance and maintained that the quarter supports meaningful 2027 margin recovery and a 3% Individual Medicare Advantage margin in 2028.

Several firms had already improved their stance before the quarter. Raymond James upgraded HUM to Outperform from Market Perform with a $520 target. Truist raised its target to $475 from $415 while keeping Hold. UBS raised its target to $495 from $405 with a Neutral rating, and Oppenheimer raised its target to $525 from $475 while keeping Outperform. Those actions created a constructive baseline before the new results arrived.

The quarter should not change our view for meaningful 2027 margin recovery and a 3% Individual Medicare Advantage margin in 2028.

- David Windley, Jefferies

Management Commentary: A Recovery Plan With Milestones

We have just one headline today, and that is that we are in a good place.

- James Rechtin, CEO, Earnings Call

CEO James Rechtin framed the quarter as evidence that Humana's strategy is moving from plan toward ahead of plan. He pointed to four operating drivers: product experience, clinical results, efficient operations, and capital allocation. Annual enrollment performance is ahead of initial expectations, planned-exit member retention is strong, and new sales are ahead of plan. Management currently expects 2027 membership to increase.

The strongest strategic data point was the BY28 Stars result. Humana reached a 4.17 member-weighted rating, which exceeded its top-quartile goal. Rechtin said the company expects a one-time tailwind in 2028, then plans to use part of it to strengthen Stars capabilities and improve customer experience. He also expects a portion to flow to shareholders.

Our performance to date supports an increase in our full year adjusted EPS outlook from at least $9 to at least $9.50.

- Celeste Mellet, CFO, Earnings Call

Mellet supplied the financial bridge. She said cost trends were in line with or better than expectations, reserves continued to build, and Humana remained on track to double its individual Medicare Advantage pretax margin in 2026, excluding the Stars headwind.

Balance-sheet efficiency also improved. Humana expects roughly $900M in pretax proceeds from its Gentiva minority-interest divestment. The new BlackRock joint venture is expected to reduce GAAP debt-to-capital by about 130 basis points in Q4. It also removes the need to fund a 2027 put option that otherwise would have increased debt-to-capital by about 130 basis points.

HUM Earnings Call Q&A Highlights

Wells Fargo analyst Stephen Baxter pressed management on the 2027 bridge, including possible headwinds, tailwinds, and the expected improvement in individual Medicare Advantage margins.

I was hoping you could expand a little bit more on the 2027 commentary, maybe a potential list of headwinds and tailwinds.

- Stephen Baxter, Wells Fargo

We don't have any known headwinds other than carrying the Stars headwind we have from this year.

- Celeste Mellet, CFO, Earnings Call

Mellet listed operating transformation, Medicaid and primary-care J-curves, improved product pricing, and fewer new members as the main tailwinds. She declined to set a precise 2027 margin endpoint because membership size and mix remain tied to annual enrollment results. Still, she described improvement as material on both Stars-adjusted and unadjusted bases.

Wolfe Research analyst Justin Lake pushed on two pressure points: medical cost trends and a material year-over-year decline in one CenterWell area.

The year-over-year decline was pretty material, and you talked about one specific market and group of patients being pressured.

- Justin Lake, Wolfe Research

We're at the lower end of the range that we had expected for the year, which was 7% to 8%.

- Celeste Mellet, CFO, Earnings Call

Mellet focused her response on inpatient performance, value-based providers, and Part D favorability. The exchange reinforced the central tradeoff in the Humana Inc. earnings analysis: insurance cost control is improving, while CenterWell still contains pockets of operating pressure.

Bottom Line

HUM earnings showed better near-term execution, a raised 2026 EPS floor, strong Stars performance, and a clearer path toward 2027 margin recovery and a 3% plus Medicare Advantage margin in 2028. The volatile EPS history still demands discipline, but the combination of cost control, membership growth, and balance-sheet progress gives Humana a more credible recovery case than it had earlier in 2026.

Read the full HUM research report
▌Common Questions

Frequently asked questions

+Did Humana beat earnings in the third quarter?
Yes. Humana reported adjusted EPS of -$0.70, better than the -$1.00 consensus estimate, and revenue of $41.16 billion versus $40.87 billion expected.
+Why did Humana stock rise after the Q3 earnings report?
HUM shares rose 3.82% to $427.50 because the company beat both EPS and revenue estimates and raised its 2026 adjusted EPS outlook to at least $9.50. Investors also reacted positively to improving medical cost trends and management's more confident recovery outlook.
+What did Humana say about its 2026 earnings guidance?
Humana raised its 2026 adjusted EPS outlook to at least $9.50 from at least $9.00. That higher guide suggests management sees a stronger path to profitability as costs stabilize and operations improve.
+What were the key operational trends in Humana's quarter?
CenterWell Primary Care added nearly 147,000 members, representing 30% growth, and Medicaid membership increased by 104,000 in 2026. Management also said the 2026 medical cost trend was running at the lower end of the 7% to 8% range, which supports margin recovery.
▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌The Full Report

Want the full picture on HUM?

The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

Read the HUM report →Get Full Access →

Not ready to subscribe? ·

▌The Full Report

Get the full HUM research report

  • Analyst-grade deep dive
  • Charts, valuation, grades
  • Buy/sell price targets
Read the HUM report →
▌For Active Investors

Smarter research, on every ticker

  • Daily market intelligence
  • On-demand stock analysis
  • AI analyst chat
Get Full Access →

Cancel anytime

▌The Daily Briefing · Free

A new stock idea, every evening.

One stock worth watching each weekday, free in your inbox.

Creates a free TickerSpark account — newsletter included.

or with email

Daily market recap + weekly preview. One-click unsubscribe in every email.

▌More on HUM

More to read

All articles
Humana Inc. (HUM) gains on earnings beats, up 4.0%
HUM

Humana Inc. (HUM) gains on earnings beats, up 4.0%

Humana Inc. (HUM) gains 4.0% after reporting earnings beats, lifting shares as investors react to stronger-than-expected quarterly results and improved outlook.

Nov 6·2 min
Humana Inc. (HUM) jumps 16% on Medicare Advantage boost
HUM

Humana Inc. (HUM) jumps 16% on Medicare Advantage boost

Humana Inc. (HUM) jumps after CMS 2027 Medicare Advantage Star Ratings showed 95% of members in plans rated 4 stars or above. The company’s flagship H5216 contract also returned to 4 stars, restoring bonus-payment eligibility and improving the outlook for revenue and margins.

Oct 9·5 min
Humana (HUM): Medicare Advantage Recovery in Progress
HUM

Humana (HUM): Medicare Advantage Recovery in Progress

Humana’s Buy case hinges on a rebound in Medicare Advantage economics, improving operating efficiency, and CenterWell growth. The stock still faces meaningful reimbursement, Star Ratings, and medical cost risk.

Oct 9·22 min